Tempus AI, Inc (TEM)
After hours:
- Zacks
Tempus Stock Up Following Collaboration Expansion in Oncology R&D
TEM's latest expanded partnership is likely to leverage multimodal real-world datasets and biological model systems in oncology R&D.
- Business Wire
Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
CHICAGO, September 26, 2024--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (TSE:4502/NYSE:TAK) that takes a data-first approach to research and development, with the aim of enhancing Takeda’s oncology research and development efforts.
- Investor's Business Daily
Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
On Monday, Tempus AI stock reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 87, up from 79 the day before. While the stock is not near an ideal entry right now, see if it is able to form and break out from a proper chart pattern.
